Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sesame Care vs VitaFusions IV

Two GLP-1 desks, one scoreboard. We put Sesame Care and VitaFusions IV head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 4 · Grade B+

Sesame Care

Visit Sesame Care Full brief →
vs
No. 285 · Grade C

VitaFusions IV

Visit VitaFusions IV Full brief →

The verdict

Sesame Care takes this head-to-head.

Sesame Care scores 87 to 63 on our six-factor Brief Score — An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.

That doesn't make VitaFusions IV a bad call — it's best for readers who want pending verification. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
52
Supply Reliability
92
71
Transparency
94
64
Access Breadth
84
50
Clinical Oversight
80
74
Track Record
92
73
Sesame CareBrief Score 87 · 63VitaFusions IV

Price, coverage & the tracker

Sesame CareVitaFusions IV
Brief Score87/100 (B+)63/100 (C)
SemaglutideFrom $149/mo (brand Wegovy pill)From $149/mo (all doses, plus a separate fee, compounded)
TirzepatideBrand Zepbound (price varies)From $189/mo (all doses, compounded)
CoverageNationwide marketplaceCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.

VitaFusions IV: New to the tracker on 1 August 2026. The published line reads From $149/mo (all doses, plus a separate fee, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.